Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma	HER2 Negative; Low PD-L1 Expressing; Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma	Recruiting	Phase 2	2026-05-07		NCT06932068

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Qilu Hospital of Shandong University	249

27 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Jining Medical College	Jining	China	5
Binzhou Medical University Hospital	Binzhou	China	10
Dezhou People's Hospital	Dezhou	China	3
Jinan Central Hospital	Jinan	China	24
Jinan Third People's Hospital	Jinan	China	2
Jining First People's Hospital	Jining	China	1
Liaocheng People's Hospital	Liaocheng	China	16
Linyi Cancer Hospital	Linyi	China	22
Linyi People's Hospital	Linyi	China	18
Qilu Hospital of Shandong University	Jinan	China	138
Qilu Hospital of Shandong University(Qingdao)	Qingdao	China	2
Qingdao Municipal Hospital	Qingdao	China	10
Shandong Provincial Hospital Affiliated to Shandong First Medical University	Jinan	China	5
Shandong Provincial Third Hospital	Jinan	China	2
Shandong Qianfoshan Hospital	Jinan	China	1
Shengli Oilfield Central Hospital	Dongying	China	4
Taian City Central Hospital	Tai’an	China	1
Tengzhou Central People's Hospital	Tengzhou	China	2
The Affiliated Hospital of Qingdao University	Qingdao	China	48
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	125
The Second Affiliated Hospital of Shandong First Medical University	Tai’an	China	1
Weifang Hospital of Traditional Chinese Medicine	Weifang	China	3
Weihai Central Hospital	Weihai	China	2
Yantai Yuhuangding Hospital	Yantai	China	19
Yantaishan Hospital	Yantai	China	2

Clinical trials